Bristol Myers Squibb has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma®.
Bristol Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma®, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for patients…